The factor Xa inhibitor rivaroxaban failed in reducing the risk of death, MI or stroke as compared with placebo among patients with worsening chronic heart failure (HF) and underlying coronary artery disease (CAD) without atrial fibrillation (AF), according to results of the COMMANDER HF trial reported at the European Society of Cardiology (ESC) Congress 2018.
Lorcaserin has become the first weight-loss agentto show cardiovascular (CV) safety in patients at high CV risk, according to results of the CAMELLIA–TIMI 61 study presented at the European Society of Cardiology (ESC) Congress 2018.
Drug-coated balloons (DCB) are noninferior to drug-eluting stents (DES) for the management of small native coronary artery disease (CAD), according to results of the BASKET-SMALL 2 trial presented at the European Society of Cardiology (ESC) Congress 2018.
Tafamidis, an oral disease-modifying agent used to delay the loss of peripheral nerve function in transthyretin amyloid polyneuropathy (ATTR-PN), is shown to improve survival and reduce hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTR-ACT trial.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.